Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Peter Riley

Cardiovascular Disease Richmond, VA Medical Doctor

NPI 1154709566 CMS profile 1356963

8700 Stony Point Pkwy Ste 120, Richmond, VA 23235

Open in the dashboard

General payments

$9,410

169 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Peter Riley of Richmond, VA is reported in the CMS Open Payments database as having received $9,410 across 169 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,331 54
2024 General $4,617 49
2023 General $1,641 26
2022 General $1,406 17
2021 General $79 3
2020 General $45 3
2019 General $291 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Peter Riley
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Peter Riley were reported at $1,331. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Peter Riley Cardiovascular Disease median Middle half National median
2019 $291 $450 $127–$1,392 $163
2020 $45 $242 $77–$751 $114
2021 $79 $335 $101–$1,037 $132
2022 $1,406 $395 $121–$1,211 $149
2023 $1,641 $443 $136–$1,283 $160
2024 $4,617 $450 $136–$1,323 $164
2025 $1,331 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $3,972 24 payments
  2. Shockwave Medical, Inc $1,068 14 payments
  3. Novartis Pharmaceuticals Corporation $723 36 payments
  4. Boston Scientific Corporation $559 7 payments
  5. Medtronic, Inc. $287 6 payments
  6. Teleflex LLC $264 3 payments
  7. W. L. Gore & Associates, Inc. $196 2 payments
  8. Biotronik Inc. $195 3 payments
  9. Abiomed $186 5 payments
  10. Kestra Medical Technology Services, Inc. $174 3 payments
  11. Other $1,786 66 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,135 164 payments
  2. Travel and Lodging $2,275 5 payments
Products named General payments · program years 2019–2025
  1. OPTIS $3,154 14 payments
  2. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Lithoplasty $796 10 payments
  3. LEQVIO $552 26 payments
  4. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Cardiology $248 3 payments
  5. CARDIOMEMS $236 2 payments
  6. GORE CARDIOFORM Septal Occluder $196 2 payments
  7. Orsiro Mission $195 3 payments
  8. Diamondback Coronary $193 3 payments
  9. General - Structural Heart $173 1 payment
  10. ENTRESTO $171 10 payments
  11. Other $3,816 100 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

437

Median for Interventional Cardiology: 2,236

Drug cost

$22,312

Median for Interventional Cardiology: $380,412

Branded share of claims

41.2%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 25 $18,583
Clopidogrel Clopidogrel Bisulfate Brand 120 $1,309
Prasugrel Hcl Generic 13 $763
Metoprolol Succinate Generic 46 $521
Atorvastatin Calcium Generic 41 $273
Rosuvastatin Calcium Generic 31 $222
Isosorbide Mononitrate Er Isosorbide Mononitrate Brand 35 $153
Losartan Potassium Generic 11 $112
Nitroglycerin Generic 12 $107
Spironolactone Generic 16 $92

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 58 billing codes

Paid by Medicare

$114,085

Medicare's payments for the services billed

Medicare patients

537

Average age 77

Services billed

1,542

269 women, 268 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 71%
Heart failure 56%
Arthritis 52%
Diabetes 51%
Atrial fibrillation 46%
Chronic kidney disease 43%
COPD 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
$151 — —
Repatha
$63 — —
EVKEEZA
$33 — —
RYBELSUS
$27 — —
Ozempic
$27 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

169 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record